Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.

Autor: Muniesa C; Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Dermatology, Hospital de Viladecans, Viladecans, Barcelona, Spain., Gallardo F; Department of Dermatology, Hospital del Mar, IMAS-IMIM, Barcelona, Spain., García-Doval I; Research Unit, Fundación Piel Sana AEDV, Madrid, Spain., Estrach MT; Department of Dermatology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain., Combalia A; Department of Dermatology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain., Morillo-Andújar M; Department of Dermatology, Hospital Universitario Vírgen del Rocío, Sevilla, Spain., De la Cruz-Vicente F; Department of Hematology, Hospital Universitario Vírgen del Rocío. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain., Machan S; Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain., Moya-Martínez C; Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain., Rovira R; Department of Dermatology, Hospital del Mar, IMAS-IMIM, Barcelona, Spain., Sanchez-Gonzalez B; Department of Hematology, Hospital del Mar, IMAS-IMIM, Barcelona, Spain., Acebo E; Department of Dermatology, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain., Amutio E; Department of Hematology, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain., Peñate Y; Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran, Canaria, Las Palmas, Spain., Losada-Castillo MDC; Department of Hematology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran, Canaria, Las Palmas, Spain., García-Muret MP; Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain., Iznardo H; Department of Dermatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain., Román-Curto C; Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain., Cañueto J; Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain., Fernández-de-Misa R; Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Flórez Á; Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain., Izu RM; Department of Dermatology, Hospital de Basurto, Bilbao, Spain., Torres-Navarro I; Department of Dermatology, Hospital Universitario La Fe, Valencia, Spain., Zayas A; Department of Dermatology, Hospital Universitario Dr Peset, Valencia, Spain., Pérez-Paredes G; Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Blanes M; Department of Dermatology, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain., Yanguas JI; Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Navarra, Spain., Pérez-Ferriols A; Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain., Callejas-Charavia M; Department of Hematology, Hospital Príncipe de Asturias, Madrid, Spain., Ortiz-Romero PL; Department of Dermatology, Hospital Universitario 12 de Octubre, Institute I+12 Research Institute, Universidad Complutense, Madrid, Spain., Pérez-Gil A; Department of Dermatology, Hospital Universitario Vírgen de Valme, Sevilla, Spain., Prieto-Torres L; Department of Dermatology, Hospital Universitario Lozano Blesa, Zaragoza, Spain., González-Barca E; Department of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L'Hospitalet de LLobregat, Barcelona, Spain., Servitje O; Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Jan; Vol. 37 (1), pp. 57-64. Date of Electronic Publication: 2022 Sep 09.
DOI: 10.1111/jdv.18563
Abstrakt: Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.
Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL.
Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).
Results: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.
Conclusions: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
(© 2022 European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: